Background
Tumour-infiltrating lymphocytes (TILs) have been established as a predictive biomarker for response to neoadjuvant chemotherapy irrespective of molecular subtype [
1]. The evidence is most pronounced in triple-negative and HER2-positive breast cancer, and likewise, increased TILs are a strong prognostic factor for improved survival in early triple-negative and HER2-positive breast cancer [
2,
3]. In contrast, the presence of TILs has in oestrogen receptor-positive (ER+) breast cancer been suggested to be an adverse prognostic factor and associated with poor response to aromatase inhibitors [
1,
4,
5]. While the composition and dynamics of TILs are complex, several studies have shown that the predictive information from immune gene expression analyses correlates well with TIL count on haematoxylin and eosin-stained slides [
6,
7].
Neoadjuvant studies have a major strength that by comparing sequential specimens from patients before and after treatment it is possible to obtain predictive and prognostic information using tumour response, linking biology with clinical response. Response to neoadjuvant treatment can be used to stratify post neoadjuvant treatment. Pathological complete response (pCR) has been the most commonly used endpoint in neoadjuvant trials, but a low pCR rate in ER+ breast cancer makes pCR a less than ideal endpoint in this population. Different pathological scoring systems for residual disease (RD) exist including the Miller-Payne grading system, which estimates a decrease in cellularity during treatment [
8], and the Residual Cancer Burden (RCB) index that take tumour dimensions, cellularity of the tumour bed and axillary nodal burden into account [
9,
10]. For neoadjuvant endocrine treatment, the Preoperative Endocrine Therapy Prognostic Index (PEPI) score has been applied in some occasions [
11]. The PEPI score is however not routinely used mainly due to the lack of standardisation and validity of Ki67 scoring [
12].
In this study, we investigated the dynamics of TILs and relationship to pathological outcome during neoadjuvant endocrine therapy.
Discussion
We found that an increase in TILs during neoadjuvant letrozole was associated with a poor treatment response, regardless of the pathological assessment method. Furthermore, TILs were positively correlated with Ki67 levels both before and after 4 months of letrozole. A high Ki67 index is indicative for a luminal B subtype, which harbours a greater genomic instability than luminal A [
19]. A high number of mutations increase the chance that mutated protein sequences will be exposed and recognised as neo-antigens by the immune system, hereby activating the immune system and promoting lymphocytic infiltration of the tumour area. The relationship between Ki67 and TILs in ER+, HER2 normal breast cancer has been examined by others with differing results. Denkert et al. [
2] showed that stratifying ER+, HER2 normal breast cancers in high/low Ki67 did not change the overall prognostic effect of TILs, whereas Fujimoto et al. [
20] demonstrated that high TILs were associated with favourable DFS in Ki67-high, but not in Ki67-low ER+, HER2 normal breast cancer. As more data will become available, we will gain a deeper understanding of the interaction between the tumour, its microenvironment and the adaptive immune activation system and the implications for prognosis and treatment efficacy.
Our data confirms previous finding by our group and others that tumours of non-ductal histologic subtype predict a poor response to neoadjuvant therapy [
13,
21,
22].
Contradictory results regarding TILs were found by Liang et al. in the CARMINA 02 trial [
23]. When assessing 83 patients treated with endocrine treatment, they found TILs increased in responders but remained stable in non-responders. As in our study, pretreatment levels of TILs did not predict response. The dissimilarities in our results call for testing in larger studies and alignment of pathological assessment method used. Baseline TILs in our population ranged between 0 and 50%, which is consistent with the data from Stanton et al. [
24] showing that 94% of ER+ menopausal breast cancer patients had less than 49% TILs when diagnosed (
n = 2410). Our data supports that of others that ER-positive tumours with higher lymphocytic infiltration have reduced benefit from aromatase inhibitor treatment [
4].
The current study has some limitations. Firstly, the small sample size in the study results in a limited power, and secondly, we do not have knowledge of the composition of immune cells beyond TIL count in our population. The strengths of our study include prospectively planned diagnostic and pathological procedures uniformly carried out with central assessment after international recommended guidelines. Patient treatment and follow-up are performed according to DBCG national guidelines [
25]. A general limitation for neoadjuvant endocrine studies is the lack of validated methods for response evaluation. The Miller-Payne grading system and the RCB index is both developed and validated in neoadjuvant studies for chemotherapy and does not necessarily translate into the neoadjuvant endocrine setting. The PEPI score, which has been applied in the neoadjuvant endocrine setting, lacks analytical validity across laboratories rendering it, so far, only feasible for research [
12]. The results from this study indicate that RCB might be used for the measurement of neoadjuvant endocrine treatment response since an increase in TILs during treatment was predictive for a poor response, irrespective of the applied response evaluation method.
More knowledge is needed to predict response to endocrine treatment based on the dynamic and composition of TILs, especially more detailed knowledge on the composition of immune cells in luminal breast cancer. Previous studies on TILs in breast cancer identified lymphocyte populations that were mainly comprised of CD8+ cytotoxic T cells and CD4+ regulatory cells together with varying proportion of other helper T cells, B cells and NK cells [
26]. CD8+ is the key immune cell for tumour cell elimination, working partly through cytotoxic granule release mediated by Granzyme B (GrB) [
24,
27]. The only known human intracellular inhibitor of GrB is serine proteinase inhibitor 9 (PI-9). In vitro studies have revealed that elevated levels of oestrogen receptor alpha induce PI-9 [
27]. In postmenopausal women, circulating oestrogen is on average 50 pM, which is sufficient to induce PI9 [
27,
28]. Another study investigating lymphocyte composition changes during neoadjuvant endocrine treatment found that oestrogen depletion resulted in a significant increase of the CD8+/Treg ratio [
29].
Breast cancer in general, and especially luminal breast cancer, is considered non-immunogenic, and immunotherapy has yet to have a place in the adjuvant setting for breast cancer patients. TIL count and modulation of immune response could be used to select patients for inclusion in adjuvant immunotherapy trials. Additionally, it is rational to enhance the anti-tumour immune response prior to potential immunotargeted treatment. CDK4/6 inhibitors promote the recruitment of TILs, as a result of several mechanisms including enhanced tumour antigen presentation, reduced proliferation of immunosuppressive regulatory T cells and a direct stimulatory effect on T cells [
30,
31]. Although these results are from preclinical studies, the possibilities are promising and possible combinations with targeted and immunotherapy are currently being investigated both in laboratories and in clinical trials.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.